AC Immune - Full Week-100 Results From Part 1 VacSYn Trial Expected In H2 2026 - ACIU News | RalliesAC Immune - Full Week-100 Results From Part 1 VacSYn Trial Expected In H2 2026
A
ACIU• VacSYn trial timing
- Full week-100 results from Part 1 of the VacSYn trial are expected in H2 2026.
Fast Track designation for ACI-7104
- AC Immune receives FDA Fast Track designation for anti-alpha-synuclein active immunotherapy, ACI-7104, to treat early Parkinson’s disease (PD).
- AC Immune said interim results show safety and immunogenicity with early signals of activity for ACI-7104.
FERG
•
